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In 1981 it was observed that the infusion of atrial tissue extract into rats caused
natriuresis.1 This led to the discovery of atrial natriuretic peptide.  Subsequent
research has established that the various natriuretic peptides have a role in the
body's defence against hypertension and plasma volume expansion.2 The natri-
uretic peptide family consists of three types:  atrial natriuretic peptide (A-type),
brain natriuretic peptide (B-type), secreted by the ventricle, and C-type peptide,
originating in the endothelium.2
In left ventricular dysfunction, regardless of the cause, the neurohormonal system
is activated, consisting of the:
• sympathetic nervous system
• renin-angiotensin-aldosterone pathway
• endothelin pathway.
These three systems, once activated, may initially compensate for the haemody-
namic derangements that follow from left ventricular dysfunction, but eventually
they become toxic to the heart and contribute to the clinical syndrome of heart
failure.
Natriuretic peptides, on the other hand, are also stimulated in left ventricular dys-
function, but they represent the favourable side of neurohormonal activation for
they actually endeavour to oppose the actions of the renin-angiotensin-aldos-
terone system, in addition to causing vasodilatation and natriuresis.3 These
changes are represented in Fig. 1.
PATHOPHYSIOLOGY
The release of natriuretic peptides into the circulation is stimulated by myocyte
stretching of the failing myocardium.2 The concentration in the plasma of natri-
uretic peptide is correlated with the extent of ventricular dysfunction, rising by as
much as a factor of 30 in patients with advanced heart failure (New York Heart
Association grade IV).4
Increasing plasma natriuretic peptide concentrations in patients with heart failure
are also correlated with the development of cardiac arrhythmias and the degree
of haemodynamic compromise in heart failure and furthermore predict long-term
survival.5 In clinical medicine, the natriuretic peptide that has found its way into
clinical practice is the B-type (BNP).  BNP is specifically secreted by the ventricles
under pathological conditions.
B-type natriuretic peptide 
The major site of origin of BNP under pathological conditions (ventricular stretch
or increased wall tension) are the ventricles.6 In Fig. 2 it is demonstrated that 
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The importance of the various natriuretic peptides has become more apparent over the
years.
The release of natriuretic
peptides into the circula-
tion is stimulated by
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pro-BNP is split into BNP and an
amino-terminal BNP (NT-pro-BNP).
Currently NT-proBNP can be 
measured quite readily and the test is
available in South Africa.
BNP: clinical utility
BNP is an effective way to ‘rule out’
heart failure or left ventricular dysfunc-
tion in patients with symptoms sugges-
tive of heart failure, especially dysp-
noea.7
Patients presenting in the emergency
room with acute dyspnoea had a BNP
level of 100 pg/ml with a sensitivity
of 90% and a specificity of 73% in the
diagnosis of heart failure.  Two other
studies confirmed this use of BNP in
acute dyspnoea to rule out heart fail-
ure.8,9
The rapid BNP measurement in the
emergency unit to diagnose heart fail-
ure, has demonstrated a diagnostic
accuracy of BNP at a level of 100
pg/ml of 83.4%, with a negative pre-
dictive value at a level < 50 pg/ml of
96% and a receiver operating charac-
teristic (ROC) curve of 0.91 (95% Cl:
0.90 - 0.93).
Statistical figures like these confirm the
usefulness of BNP measurements to
rule out heart failure in patients pre-
senting with dyspnoea but no other
overt clinical signs of heart failure.
Comparative accuracy of
BNP 
In a study various methods to diag-
nose heart failure were compared.
When the Framingham criteria for
heart failure were used, the diagnostic
accuracy was 75%.  In comparison,
the diagnostic accuracy of raised BNP
levels was 83%.10 
In a general community
population 
NT-proBNP performance in diagnosing
heart failure in the community was test-
ed in a study which demonstrated that
a NT-proBNP level of > 36 pmol/l had
a sensitivity of 100%, and a specificity
of 70%, with a positive predictive
value of 7% and a negative predictive
value of 100%.  The ROC-curve was
0.92 (95% Cl: 0.82 - 1.0).  The low
positive predictive value may pose a
problem in using BNP as a screening
test in the general population because
of a large number of ‘false’ positives.
BNP may therefore not be useful in
screening asymptomatic populations to
diagnose heart failure.
In summary, it can be stated that the
main value of NT-proBNP (or BNP) is
to rule out heart failure in symptomatic
patients where a diagnosis of heart
failure is suspected.11
BNP levels in systolic and
diastolic LV dysfunction 
In a study comparing diastolic LV dys-
function and systolic dysfunction, both
diagnosed on echocardiography, BNP
levels were measured in both condi-
tions and in healthy controls as a com-
parison:12
• in diastolic dysfunction BNP levels
were 445 ± 150 pg/ml
• in systolic dysfunction BNP levels
were 1 660 ± 404 pg/ml
• in healthy age-matched controls
BNP levels were 24 ± 4 pg/ml.  
This study shows that BNP levels are
raised in all types of heart failure,
more so in systolic dysfunction.
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Prolonged activation directly toxic
to heart via apoptosis, myocyte,
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Fig. 1. Neurohormonal activation in heart failure.
Prognosis in heart failure
BNP can also be used to determine
the prognosis of patients with heart
failure.  BNP has been used as a risk
stratification in patients with heart fail-
ure when the BNP level is more than
440 pg/ml on admission.  The sensi-
tivity is 74% and specificity is 59% to
predict future events in heart failure
patients.13
In the Val-HeFT-trial, BNP values over
36 months were used to determine the
prognosis of patients with heart fail-
ure.  If the BNP (pg/ml) level was 
< 41; 41 – < 97; 97 – < 238 or 
≥ 238, the corresponding mortality
was 9.7%, 14.3%, 20.7% and
32.4%.
In summary, it can be stated that in
heart failure, the higher the BNP level
(including NT-proBNP), the worse the
prognosis.
BNP levels in heart failure patients
may also have other uses.  Patients
with heart failure whose BNP levels
fell below 1 220 pg/ml at discharge 
were less likely to be readmitted with
worsening heart failure.14
In heart failure patients with BNP lev-
els of more than 480 pg/ml, the 
6-month probability of admission or
death was 42%.  If, however, the BNP
level was < 230 pg/ml, there was
only a 2% probability of such an
event.15
BNP level may serve as a prognostic
marker for sudden death in heart fail-
ure, presumably due to a dysrhythmia.
The BNP level was the only predictor
for sudden death in heart failure
patients with LVEF < 35% followed for
3 years.16 The BNP had a cut-off level
of 130 pg/ml in predicting sudden
death.  Could this be used in future as
an indicator for the insertion of an
intracardiac defibrillator (ICD) in heart
failure patients?  Practical applications
like these need to be explored further.
Assessment of treatment
efficacy in heart failure
BNP levels fall after treatment with a
loop diuretic and ACE inhibitors.17
In NT-proBNP guided treatment, 69
patients with a LVEF of < 40%, treat-
ment was assigned according to clini-
cal criteria or according to NT-proBNP
level.  At 6 months, 27% of patients in
the BNP group and 53% in the clini-
cally guided group had a first cardio-
vascular (CV) event.18 BNP levels can
also be used as a marker of the effects
of ACE inhibition.19
Prognosis in acute coronary
syndrome (ACS)
The BNP level can be used to deter-
mine prognosis after an acute myocar-
dial infarction (AMI).  If BNP or NT-
proBNP levels were combined with
LVEF measurements, there was an
improved prognostic risk prediction in
patients with ACS.20
In another study to predict prognosis
using BNP, 204 patients with an 
ST-segment-elevated myocardial infarc-
tion (STEMI), 220 with non-ST-segment
elevated MI (non-STEMI) and 185 with
unstable angina were investigated.
Follow-up was 51 months.  The NT-
proBNP was lower (442 pmol/l) in
survivors than in patients who died
(1 306 pmol/l).  The NT-proBNP level
added prognostic information above
and beyond Kilip class, age, and LVEF
in patients with an ACS.  Even peak
troponin T levels did not alter the rela-
tionship.21
In summary, elevated NT-BNP levels
are highly predictive of a worse out-
come in the ACS. 
Risk stratification in acute
pulmonary embolism (PE)
The risk of death due to PE if the BNP
level is > 21.7 pmol/l, is 17% (95%
Cl:  6 - 33%).  The negative predictive
value for an uneventful outcome of a
BNP value < 21.7 pmol/l is 99%
(95% Cl:  93 - 100%).22
The optimal BNP cut-off level deter-
mined by ROC curve is < 50 pg/ml.
A cut-off level of < 80 pg/ml identifies
95% of patients with a benign course
after a PE.  
An NT-proBNP level of < 500 pg/ml
had a negative predictive value for 
adverse outcome of 97% (95% Cl:
84 - 99%) in patients with PE.23
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Cleared by natriuretic peptide C
receptor (clearance receptor) in
kidney, lungs, vascular walls
• No known biological function
• Easier to obtain a high analytical
precision with the test
• Levels may represent cardiac




Amino acids (1 - 76)
(1/2 life: 20 min)
(1/2 life: 1 - 2 hrs)
(1/2 life: 1 - 3 hrs)
Fig. 2. BNP: Natural history.
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In summary, NT-proBNP levels can be
used in patients with a pulmonary
embolism to predict a poor outcome.
This is probably because in a massive
pulmonary embolism, the sudden
stretching of the right ventricle causes
the release of NT-proBNP.
Role of BNP in myocardial
ischaemia
It has been demonstrated that BNP is
elevated in unstable angina, and also
elevates after balloon inflations during
coronary angioplasty.24,25 In experi-
mental ischaemia in the rat myocardi-
um of as little as 2 minutes, there is an
immediate increase in BNP.26 There is
a suggestion that BNP modifies acute
ischaemic myocardial injury and that
BNP may influence post-infarction
remodelling.27 It may be that we will
be using BNP in future as a general
indicator of cardiac structural disease
rather than a specific indicator of sys-
tolic dysfunction of the left ventricle
only.28 
References available on request.
NT-proBNP can be readily measured and an elevated level can be used to
diagnose, or at least select, those patients who need further investigation
for heart failure.  
A normal level of NT-proBNP will effectively ‘rule out’ heart failure, espe-
cially in those patients without overt clinical signs of heart failure.
The higher the levels of NT-proBNP in heart failure patients, patients with
an acute coronary syndrome or patients with a pulmonary embolus, the
worse the prognosis. 
In this manner elevated levels of NT-proBNP can guide the practitioner to
increase the intensity of therapy.
IN A NUTSHELL
FAST FOOD TRICKS
We all assume that people are getting fatter because they eat too much. But a
recent item in New Scientist may suggest otherwise. According to researchers
from the International Nutrition Group at the London School of Hygiene and
Tropical Medicine, it may be that our food is too rich. What they are getting at is
the energy density of the foods. Apparently, volunteers given low energy-density
foods who ate as much as they liked lost weight, while their unfortunate counter-
parts given high energy-density foods gained. The problem seems to be fast
foods. It seems that our bodies evolved to deal with an energy density of 
450 kJ/100 g, while the average burger contains about 1 200 kJ/100 g. The
typical British diet has an energy density of about 650 kJ/100 g. All you need to
do is eat 200 g of fast food too many twice a week to gain a whopping 8 kg of
body fat a year. 
(Editor’s note: Once again, more evidence for my conviction that all that matters in
weight control is calories in versus calories out — on your bikes everyone!) 
(Coghlan A. New Scientist 2003; 25 October, p.10.)
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